{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:49:30Z","timestamp":1791910170248,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16495-0","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:53:17Z","timestamp":1783936397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Curative-intent tri-modality treatment of de novo bone-only oligometastatic breast cancer: single-center patient outcomes"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2813-9964","authenticated-orcid":false,"given":"Joseff Karl","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Yang Jerome","family":"Leow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Beith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Morarji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsie","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mun","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"16495_CR1","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. https:\/\/doi.org\/10.3322\/caac.21660.\u00a0 Epub ahead of print. PMID: 33538338.","DOI":"10.3322\/caac.21660"},{"issue":"1","key":"16495_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-022-06700-6","volume":"196","author":"DM File","year":"2022","unstructured":"File DM, Pascual T, Deal AM, et al. Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer. Breast Cancer Res Treat. 2022;196(1):153\u201362. https:\/\/doi.org\/10.1007\/s10549-022-06700-6.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"16495_CR3","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/jnci\/djac158","volume":"114","author":"L Gallicchio","year":"2022","unstructured":"Gallicchio L, Devasia TP, Tonorezos E, Mollica MA, Mariotto A. Estimation of the Number of Individuals Living With Metastatic Cancer in the United States. J Natl Cancer Inst. 2022;114(11):1476\u201383. https:\/\/doi.org\/10.1093\/jnci\/djac158.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"16495_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10549-018-05090-y","volume":"174","author":"J Malmgren","year":"2019","unstructured":"Malmgren J, Hurlbert M, Atwood M, Kaplan HG. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990\u20132011. Breast Cancer Res Treat. 2019;174(2):505\u201314. https:\/\/doi.org\/10.1007\/s10549-018-05090-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"16495_CR5","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdq220","volume":"21","author":"S Dawood","year":"2010","unstructured":"Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010;21(11):2169\u201374. https:\/\/doi.org\/10.1093\/annonc\/mdq220.","journal-title":"Ann Oncol"},{"issue":"4","key":"16495_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.clbc.2021.01.017","volume":"21","author":"K Daily","year":"2021","unstructured":"Daily K, Douglas E, Romitti PA, Thomas A. Epidemiology of de novo metastatic breast cancer. Clin Breast Cancer. 2021;21(4):302\u20138. https:\/\/doi.org\/10.1016\/j.clbc.2021.01.017.","journal-title":"Clin Breast Cancer"},{"key":"16495_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157\u201366.","journal-title":"Radiother Oncol"},{"issue":"3","key":"16495_CR8","doi-asserted-by":"publisher","first-page":"pkab010","DOI":"10.1093\/jncics\/pkab010","volume":"5","author":"TG Steenbruggen","year":"2021","unstructured":"Steenbruggen TG, Schaapveld M, Horlings HM, et al. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. JNCI Cancer Spectr. 2021;5(3):pkab010. https:\/\/doi.org\/10.1093\/jncics\/pkab010. Published 2021 Feb 4.","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"16495_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","volume":"19","author":"R Wang","year":"2019","unstructured":"Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19(1):1091. https:\/\/doi.org\/10.1186\/s12885-019-6311-z. PMID: 31718602; PMCID: PMC6852913.","journal-title":"BMC Cancer"},{"key":"16495_CR10","doi-asserted-by":"crossref","unstructured":"Bertho M, Fraisse J, Patsouris A, Cottu P, Arnedos M, Perol D. et. Al. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. Ther Adv Med Oncol. 2021; 13: 1758835920987657. Published online. 2021 Jan 21. https:\/\/doi.oeg\/10.1177\/1758835920987657.\u00a0PMCID: PMC7841864PMID: 33613700.","DOI":"10.1177\/1758835920987657"},{"key":"16495_CR11","doi-asserted-by":"publisher","first-page":"103756","DOI":"10.1016\/j.breast.2024.103756","volume":"76","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, et al. 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756. https:\/\/doi.org\/10.1016\/j.breast.2024.103756.","journal-title":"Breast"},{"issue":"16suppl","key":"16495_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","volume":"40","author":"SJ Chmura","year":"2022","unstructured":"Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, et al. NRG-BR002: a phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557. J Clin Oncol. 2022;40(16suppl):1007. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.1007.","journal-title":"J Clin Oncol"},{"issue":"25","key":"16495_CR13","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020;38(25):2830\u20138. https:\/\/doi.org\/10.1200\/JCO.20.00818.","journal-title":"J Clin Oncol"},{"key":"16495_CR14","doi-asserted-by":"publisher","unstructured":"Curigliano G, Burstein HJ, Gnant M et al. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023;34(11):970\u2013986. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.017.","DOI":"10.1016\/j.annonc.2023.08.017"},{"key":"16495_CR15","unstructured":"National Comprehensive Cancer Network. Breast Cancer. (Version 4.2024). http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed August 25, 2024."},{"issue":"2","key":"16495_CR16","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/curroncol30020108","volume":"30","author":"D Leblanc","year":"2023","unstructured":"Leblanc D, Cantin G, Desnoyers A, et al. Management of Oligometastatic Breast Cancer: An Expert Committee\u2019s Opinion. Curr Oncol. 2023;30(2):1416\u201325. https:\/\/doi.org\/10.3390\/curroncol30020108. Published 2023 Jan 19.","journal-title":"Curr Oncol"},{"key":"16495_CR17","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2024.42.16_suppl.1104","volume":"42","author":"Nicole","year":"2024","unstructured":"Nicole, Odzer, et al. Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey. JCO. 2024;42:1104\u20131104. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.1104.","journal-title":"JCO"},{"key":"16495_CR18","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1245\/s10434-020-09244-5","volume":"28","author":"K Stahl","year":"2021","unstructured":"Stahl K, Wong W, Dodge D, et al. Benefits of surgical treatment of stage IV breast cancer for patients with known hormone receptor and HER2 status. Ann Surg Oncol. 2021;28:2646\u201358.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"16495_CR19","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s12282-021-01240-1","volume":"28","author":"E Nagasaki","year":"2021","unstructured":"Nagasaki E, Kudo R, Tamura M, et al. Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report. Breast Cancer. 2021;28(5):1051\u201361. https:\/\/doi.org\/10.1007\/s12282-021-01240-1.","journal-title":"Breast Cancer"},{"key":"16495_CR20","doi-asserted-by":"publisher","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.0891","volume":"156","author":"S Samiei","year":"2021","unstructured":"Samiei S, Simons JM, Engelen SM, et al. Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: A systematic review and meta-analysis. JAMA Surg. 2021;156:e210891.","journal-title":"JAMA Surg"},{"key":"16495_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccell.2017.07.005","volume":"32","author":"LR Yates","year":"2017","unstructured":"Yates LR, Knappskog S, Wedge D, et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 2017;32:169\u201384.","journal-title":"Cancer Cell"},{"key":"16495_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ctro.2021.03.012","volume":"28","author":"D Krug","year":"2021","unstructured":"Krug D, Vonthein R, Illen A, et al. Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol. 2021;28:90\u20136. https:\/\/doi.org\/10.1016\/j.ctro.2021.03.012. Published 2021 Apr 5.","journal-title":"Clin Transl Radiat Oncol"},{"key":"16495_CR23","doi-asserted-by":"crossref","unstructured":"Linderholm BK, Valachis A, Flote VG, Poortmans P, Person OK, Niligal-Yam E, O\u2019Reilly S, Duane F, Marinko T, Ekholm M. Andersson A. 259TiP Treatment of oligometastatic breast cancer (OMBC): a randomised phase III trial comparing stereotactic ablative radiotherapy (SABR) and systemic treatment with systemic treatment alone as first-line treatment-TAORMINA. ESMO Open. 2023;8(1).","DOI":"10.1016\/j.esmoop.2023.101447"},{"key":"16495_CR24","unstructured":"Bourgier C. Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer (STEREO-SEIN). accessed 28 Feb 2021]. In: ClinicalTrials.gov. ClinicalTrials.gov Identifier: N02089100. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02089100."},{"issue":"6","key":"16495_CR25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022;386(6):556\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2112651.","journal-title":"N Engl J Med"},{"key":"16495_CR26","doi-asserted-by":"publisher","unstructured":"Schmid P, Cortes J, Dent R, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med Published online September. 2024;15. https:\/\/doi.org\/10.1056\/NEJMoa2409932.","DOI":"10.1056\/NEJMoa2409932"},{"key":"16495_CR27","doi-asserted-by":"publisher","unstructured":"Zhou Q, Gampenrieder SP, Frantal S et al. Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. Clin Cancer Res. 2022;28(4):697\u2013707. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3231 Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response - PMC (nih.gov).","DOI":"10.1158\/1078-0432"},{"key":"16495_CR28","doi-asserted-by":"publisher","first-page":"e2200148","DOI":"10.1200\/PO.22.00148","volume":"6","author":"F Cailleux","year":"2022","unstructured":"Cailleux F, et al. Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. JCO Precis Oncol. 2022;6:e2200148. https:\/\/doi.org\/10.1200\/PO.22.00148.","journal-title":"JCO Precis Oncol"},{"key":"16495_CR29","doi-asserted-by":"publisher","unstructured":"Sherene L et al. Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC). JCO 42, LBA507-LBA507(2024). https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA507.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA507"},{"issue":"2","key":"16495_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol. 2021;32(2):229\u201339. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.007.","journal-title":"Ann Oncol"},{"issue":"10422","key":"16495_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024;403(10422):171\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(23)01857-3.","journal-title":"Lancet"},{"issue":"7","key":"16495_CR32","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","volume":"22","author":"A Sahgal","year":"2021","unstructured":"Sahgal A, Myrehaug SD, Siva S, et al. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2\/3 trial. Lancet Oncol. 2021;22(7):1023\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(21)00196-0.","journal-title":"Lancet Oncol"},{"key":"16495_CR33","doi-asserted-by":"publisher","first-page":"e12574","DOI":"10.1200\/JCO.2023.41.16_suppl.e12574","volume":"41","author":"A Iancu","year":"2023","unstructured":"Iancu A, et al. Long term survival in patients with bony oligometastatic breast cancer treated with curative intent: An institutional case series. JCO. 2023;41:e12574\u201312574. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e12574.","journal-title":"JCO"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16495-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16495-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16495-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:07:37Z","timestamp":1791907657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16495-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16495"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16495-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5357989\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human Research Ethics Application was submitted to and reviewed by the Human Research Ethics Committee (HREC) of St. Vincent\u2019s Hospital (Sydney, Australia), with reference number 2024\/ETH00812. The project was determined to meet the requirements of the National Statement on Ethical Conduct in Human Research (2023) and was approved.A waiver of consent was also approved as this study was deemed to have low-to-negligible risk to participants by the St. Vincent\u2019s Research Office. The St. Vincent\u2019s Hospital HREC granted a waiver of the usual requirement of consent for the use of re- identifiable information held by state agencies, in line with the State Privacy Commissioner\u2019s Guidelines for Research and the Health Records and Information Privacy Act 2002 (NSW) and the Guidelines approved under Sect. 95\/95A of the Privacy Act 1988.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1224"}}